PA
MACK

Parallel Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Parallel Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,542
Closed -$9K – 2366
2018
Q2 		$9K Buy
+2,542
New +$16.9K ﹤0.01% 1405

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Parallel Advisors's MACK Position: Q3 2018 in Review

Parallel Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2018, closing a stake of 2,542 shares — an estimated $9K sold.

Parallel Advisors first reported a position in MACK in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2018.

  • Parallel Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Parallel Advisors sold 2,542 Merrimack Pharmaceuticals, Inc. shares in Q3 2018, an estimated $9K.
  • Parallel Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Parallel Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $9K in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2018.

Based on Parallel Advisors's 13F filing for Q3 2018, filed 1 Nov 2018.